← Leaderboards
Fatah Kashanchi
Univ Of Med/Dent Of Nj-Nj Medical School
$13,969,859
Attributed
$14,770,936
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,770,936 · 20
By mechanism
R01$7,460,315 · 3
R21$5,051,659 · 12
P30$1,012,578 · 1
R56$874,372 · 1
R29$322,012 · 1
R13$50,000 · 2
Top collaborators
- Sowmya Yelamanchili3 shared
- Choukri Ben Mamoun1 shared
- Robert Molestina1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsViralHiv-1VirusInfectionIn VitroGenetic TranscriptionAcquired Immunodeficiency SyndromeCell LineComplexIn VivoProteinsGene ExpressionPharmaceutical PreparationsT-LymphocyteMacrophagePathway InteractionsBaseAffectHiv InfectionsPlayPathogenesisInhibitor/AntagonistVirus Replication
Grant awards (59)
Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brain$379,984
R01 · FY2025 · MH · contact PI
Parasite-Derived Vesicles in Babesia virulence and Vaccine Development$874,372
R56 · FY2024 · AI
Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brain$602,343
R01 · FY2024 · MH · contact PI
Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brain$631,369
R01 · FY2023 · MH · contact PI
American Society for Intercellular Communication (ASIC)$25,000
R13 · FY2023 · TR · contact PI
American Society for Intercellular Communication (ASIC)$25,000
R13 · FY2022 · TR · contact PI
Effect on CBD on Exosome release from CNS infected cells$236,054
R21 · FY2021 · DA · contact PI
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAs$377,033
R01 · FY2020 · NS · contact PI
Effect on CBD on Exosome release from CNS infected cells$211,049
R21 · FY2020 · DA · contact PI
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAs$377,063
R01 · FY2019 · NS · contact PI
Role of extracellular vesicles in methamphetamine and HIV induced neurotoxicity$190,323
R21 · FY2019 · DA
Role of extracellular vesicles in methamphetamine and HIV induced neurotoxicity$4,340
R21 · FY2019 · DA
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAs$390,093
R01 · FY2018 · NS · contact PI
Role of extracellular vesicles in methamphetamine and HIV induced neurotoxicity$241,662
R21 · FY2018 · DA
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAs$380,000
R01 · FY2017 · NS · contact PI
A radiation-induced cellular stress activates HIV and induces killing of infected cells$228,000
R21 · FY2017 · AI · contact PI
HIV neuropathogenesis related to exosomes containing HIV non-coding RNAs$380,000
R01 · FY2016 · NS · contact PI
A radiation-induced cellular stress activates HIV and induces killing of infected cells$190,000
R21 · FY2016 · AI · contact PI
HIV-1 Inhibition Using Tat peptide derivatives$373,037
R01 · FY2015 · AI · contact PI
Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cells$222,900
R21 · FY2015 · AI · contact PI
Effect of novel cdk9 inhibitor on HIV transcription$220,928
R21 · FY2015 · AI · contact PI
HIV-1 Inhibition Using Tat peptide derivatives$373,030
R01 · FY2014 · AI · contact PI
Effect of novel cdk9 inhibitor on HIV transcription$206,843
R21 · FY2014 · AI · contact PI
Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cells$185,750
R21 · FY2014 · AI · contact PI
Basic Science$75,160
P30 · FY2014 · AI · contact PI
HIV-1 Inhibition Using Tat peptide derivatives$350,640
R01 · FY2013 · AI · contact PI
Basic Science$120,046
P30 · FY2013 · AI · contact PI
HIV-1 Inhibition Using Tat peptide derivatives$373,015
R01 · FY2012 · AI · contact PI
Basic Science$82,320
P30 · FY2012 · AI · contact PI
Basic Science$578,838
P30 · FY2011 · AI · contact PI
HIV-1 Inhibition Using Tat peptide derivatives$409,810
R01 · FY2011 · AI · contact PI
Treatment of Tat neurotoxicity through the use of Gsk3-b inhibitors$182,611
R21 · FY2011 · NS · contact PI
Treatment of Tat neurotoxicity through the use of Gsk3-b inhibitors$223,605
R21 · FY2010 · NS · contact PI
Effect of chromatin remodelers/modifiers on HIV-1 Tat activated transcription$181,875
R21 · FY2010 · AI · contact PI
HIV-1 TAR derived miRNA: Implications for Latency and Pathogenesis$165,994
R21 · FY2010 · AI · contact PI
Basic Science$156,214
P30 · FY2010 · AI · contact PI
Effect of chromatin remodelers/modifiers on HIV-1 Tat activated transcription$250,556
R21 · FY2009 · AI · contact PI
HIV-1 TAR derived miRNA: Implications for Latency and Pathogenesis$234,500
R21 · FY2009 · AI · contact PI
Mechanism of activated transcription in the new HTLV-3 virus$190,886
R21 · FY2008 · AI · contact PI
HIV-1 Inhibition using Tat Peptide Derivatives$323,735
R01 · FY2007 · AI · contact PI
Mechanism of activated transcription in the new HTLV-3 virus$232,625
R21 · FY2007 · AI · contact PI
A human stem cell mouse model for HIV expression and inhibition$185,704
R21 · FY2007 · AI · contact PI
Effect of Cdk inhibitor on HIV-1 replication$185,704
R21 · FY2007 · AI · contact PI
HIV-1 Inhibition using Tat Peptide Derivatives$333,422
R01 · FY2006 · AI · contact PI
A human stem cell mouse model for HIV expression and inhibition$229,500
R21 · FY2006 · AI · contact PI
Effect on cdk inhibitor in HIV-1 replication$229,500
R21 · FY2006 · AI · contact PI
HIV-1 Inhibition using Tat Peptide Derivatives$341,464
R01 · FY2005 · AI
Alteration of Rb in HTLV-1 transformed cells$191,250
R21 · FY2005 · AI
HIV-1 Inhibition using Tat Peptide Derivatives$341,481
R01 · FY2004 · AI
Alteration of Rb in HTLV-1 transformed cells$229,500
R21 · FY2004 · AI
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVES$259,599
R01 · FY2002 · AI
CELL CYCLE REGULATED TRANSCRIPTION BY HIV1 TRANSACT TAT$106,400
R29 · FY2002 · AI
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVES$26,707
R01 · FY2002 · AI
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVES$216,556
R01 · FY2001 · AI
CELL CYCLE REGULATED TRANSCRIPTION BY HIV1 TRANSACT TAT$106,400
R29 · FY2001 · AI
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVES$119,242
R01 · FY2000 · AI
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVES$100,692
R01 · FY2000 · AI
CELL CYCLE REGULATED TRANSCRIPTION BY HIV1 TRANSACT TAT$63,872
R29 · FY2000 · AI
CELL CYCLE REGULATED TRANSCRIPTION BY HIV1 TRANSACT TAT$45,340
R29 · FY2000 · AI